

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

CHANGE OF DATE OF BOARD MEETING

Reference is made to the date of board meeting announcement of RemeGen Co., Ltd.* (the “**Company**”) dated August 16, 2022 in relation to a meeting (the “**Board Meeting**”) of the board of directors of the Company (the “**Board**”) proposed to be held on Friday, August 26, 2022 for the purposes of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2022 (the “**Interim Results**”) and its publication.

The Board hereby announces that the date of Board Meeting will be re-scheduled to Tuesday, August 30, 2022 and it is expected that the Interim Results will be published on the same day.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
August 26, 2022

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* For identification purpose only